Evidence map›Paper›PMID 42567931›Full record

ArticleNature biotechnology2026

Reversible epiblast regionalization determines differentiation potential of human pluripotent stem cells.

Magdalena A Sutcliffe, Eugenia Wong, Steven W Wingett, Charles A J Morris, Harald Stachelscheid, Stefan Schoenfelder, Madeline A Lancaster

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Magdalena A SutcliffeMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, UK. magda.sutcliffe@mrclmb.ac.uk.
Eugenia Wong *Epigenetics Programme, Babraham Institute, Babraham Research Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-0279-7282
Steven W Wingett *MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, UK.ORCID http://orcid.org/0000-0002-2343-0711
Charles A J MorrisMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, UK.
Harald StachelscheidCore Unit Pluripotent Stem Cells and Organoids, Berlin Institute of Health at Charité - Universitätsmedizin, Berlin, Germany.ORCID http://orcid.org/0000-0002-9283-4605
Stefan SchoenfelderEpigenetics Programme, Babraham Institute, Babraham Research Campus, Cambridge, UK. stefan.schoenfelder@babraham.ac.uk.ORCID http://orcid.org/0000-0002-3200-8133
Madeline A LancasterMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, UK. madeline.lancaster@mrclmb.ac.uk.ORCID http://orcid.org/0000-0003-2324-8853

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although human pluripotent stem cells (hPSCs) can generate all tissues of the body, hPSCs in vitro frequently exhibit differentiation biases or failure that pose substantial challenges for disease modeling and regenerative medicine. The origins of these biases remain incompletely understood and extend beyond reprogramming artifacts. Here we show that loss of default neural differentiation capacity and failure to form brain organoids are linked to erosion of bivalent chromatin marks at developmental gene loci, independent of DNA methylation, driving acquisition of a posterior epiblast-like state and premature developmental gene expression. We develop a chemical chromatin restoration (CHR) approach that rescues this differentiation bias by reinstating transcriptional programs and chromatin landscapes characteristic of the competent anterior epiblast-like state, restoring broad differentiation potential. These findings establish locus-specific patterns of repressive and activating histone post-translational modifications as a tractable and experimentally targetable determinant of hPSC fate competency, and offer an effective route to rescue differentiation-compromised hPSC lines for applications in disease modeling and regenerative medicine.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.